• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE’24  • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE’24  • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“at ...

NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Firesid ...

atai Life Sciences N.V. (ATAI) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of ...

Core Viewpoint - Investing in cheap drug developer stocks can be exciting yet risky, as these stocks can rapidly increase in value due to significant events like regulatory approvals and clinical trial results [1] Group 1: Scynexis (SCYX) - Scynexis has seen a dramatic decline of 98% since its IPO in 2014, previously trading over $100 [2] - The company focuses on anti-fungal treatments, particularly targeting the Candida genus, which poses challenges in treatment but is crucial for immunocompromised patients [2] - Scynexis has two effective treatments co-developed with GSK and is working on an experimental treatment, SCY-247, aimed at drug-resistant strains of Candida [3] Group 2: Atai Life Sciences (ATAI) - Atai Life Sciences is focusing on alternative mental health therapies through psychedelic compound research, with a pipeline that includes drugs based on ketamine, psilocybin, and DMT [4][5] - The flagship drug, COMP360, is in Phase-3 clinical trials and has shown over 30% remission in drug-resistant major depressive disorder patients during a 12-week trial [5] - Atai is currently trading at a 93% discount from its IPO, making it a potentially valuable investment if positive developments occur [5] Group 3: Atossa Therapeutics (ATOS) - Atossa Therapeutics is focused on disease prevention, particularly breast cancer, with its promising drug KarismaEndoxifen having completed recent clinical trials [6] - Positive trial results could significantly enhance Atossa's stock potential, as the company is dedicated to combating breast cancer [6] - Atossa is also supporting a trial for AI-based breast cancer diagnosis, which adds to its innovative approach [6]

While the cannabis industry has all but become legitimate in the United States, it’s not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored.As such, several newly minted public companies have begun experimenting with ways to harness the therapeutic potential of these compounds. When these companies first ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ:ATAI) ("atai" or "Company"), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company's participation: Format: Virtual fireside chat and 1x1 investor meetingsDate and Time: Fireside chat available ...

NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company’s participation: Format: Virtual fireside chat and 1x1 investor meetingsDate and Time: Fireside chat availabl ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

ELE-101 is a patent-protected, synthetic formulation of psilocin, designed to offer the therapeutic benefits of psilocybin in a more consistent, controllable, and shorter treatment paradigm of approximately two hours.The Phase 2a part of the study will evaluate the safety, tolerability, subjective effects, and efficacy of a single intravenous (IV) dose of ELE-101 in 6-12 participants with Major Depressive Disorder (MDD). Results are expected in H2 2024.The dose for Phase 2a was selected using preliminary ph ...